Literature DB >> 3663449

Cyclosporin-phenytoin interaction: re-evaluation using metabolite data.

M Rowland1, S K Gupta.   

Abstract

1 Freeman et al. (1984) evoked enzyme induction to explain the lower plasma concentration of cyclosporin following phenytoin co-administration in man. 2 We have examined the whole blood concentration data of two metabolites of cyclosporin, as well as unchanged drug, all measured by h.p.l.c., associated with the above mentioned study. 3 Phenytoin produced no significant effect on either the terminal half-life of both metabolites or the ratio of area under the concentration-time curve of metabolite to parent drug. 4 These data strongly suggest that phenytoin reduces the absorption of cyclosporin; they do not generally support the idea that phenytoin induces cyclosporin metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663449      PMCID: PMC1386254          DOI: 10.1111/j.1365-2125.1987.tb03177.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Comparative pharmacokinetics of coumarin anticoaglulants XLI: Effect of phenobarbital on systemic availability of orally administered dicumarol in rats.

Authors:  J W Crow; M Gibaldi; G Levy
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

2.  Studies on the increased biliary flow produced by phenobarbital in rats.

Authors:  C D Klaassen
Journal:  J Pharmacol Exp Ther       Date:  1971-03       Impact factor: 4.030

3.  Griseofulvin-phenobarbital interaction in man.

Authors:  S Riegelman; M Rowland; W L Epstein
Journal:  JAMA       Date:  1970-07-20       Impact factor: 56.272

4.  Interaction between cyclosporin A and phenobarbitone.

Authors:  H Carstensen; N Jacobsen; H Dieperink
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

5.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

6.  Interaction between phenytoin and cyclosporine following organ transplantation.

Authors:  P A Keown; A Laupacis; G Carruthers; M Stawecki; J Koegler; F N McKenzie; W Wall; C R Stiller
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

7.  Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites.

Authors:  G Maurer; H R Loosli; E Schreier; B Keller
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

8.  Griseofulvin---phenobarbital interaction: a formulation-dependent phenomenon.

Authors:  F Jamali; J E Axelson
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

9.  Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites.

Authors:  D J Freeman; A Laupacis; P A Keown; C R Stiller; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

10.  Effect of heptabarbital on bioavailability of bishydroxycoumarin in the rat.

Authors:  L Putcha; P Nandiwada; S Feldman; J V Bruckner; W G Kramer
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-01
  10 in total
  13 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Mechanism of the ketoconazole-cyclosporin interaction.

Authors:  E Ah-Sing; T W Poole; C Ioannides; L J King
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

5.  Bioavailability and absorption kinetics of nicotine following application of a transdermal system.

Authors:  S K Gupta; N L Benowitz; P Jacob; C N Rolf; J Gorsline
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

6.  Erythromycin enhances the absorption of cyclosporin.

Authors:  S K Gupta; A Bakran; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 7.  Population pharmacokinetics of cyclosporine in transplant recipients.

Authors:  Kelong Han; Venkateswaran C Pillai; Raman Venkataramanan
Journal:  AAPS J       Date:  2013-06-18       Impact factor: 4.009

8.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients.

Authors:  A Tartara; C A Galimberti; R Manni; L Parietti; C Zucca; H Baasch; L Caresia; W Mück; N Barzaghi; G Gatti
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 9.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 10.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.